[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$arwrs
Breaking: $ARWR's upcoming INHBE data in January could attract big pharma interest if it confirms recent positive results. Analysts are also noting positive sentiment around REDEMPLO's approval and expanded use.
About $arwrs
$ARWR is a cryptocurrency project focused on decentralized finance.
Insights
- $arwrs creators is up XXXXXX% from the previous month.
- $arwrs mentions is up XXX% from the previous month.
- $arwrs Mentions hit a 52-Week high of X for the day
- $arwrs Mentions hit an all time of X for the day
Engagements: XX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXXXX -XX%
X Month: XXXXXX +670%
X Months: XXXXXX +269%
X Year: XXXXXX +56%
1-Year High: XXXXX on 2025-11-18
1-Year Low: X on 2025-08-12
Engagements by network (24h): X: XX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX +50%
X Month: XX +350%
X Months: XX +189%
X Year: XX +125%
1-Year High: X on 2025-12-05
1-Year Low: X on 2024-12-23
Mentions by network (24h): X: X
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $arwrs in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X +17%
X Month: XX +233%
X Months: XX +114%
X Year: XX +91%
1-Year High: X on 2024-12-13
1-Year Low: X on 2024-12-23
The most influential creators that mention $arwrs in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BioBoyScout | X | XXXXX | X | XX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XXX%
X Year: XXX% no change
1-Year High: XXX% on 2024-12-13
1-Year Low: XXX% on 2024-12-13
Most Supportive Themes:
- Pipeline and Trial Advancements: (40%) Posts highlight progress in clinical trials and pipeline development, suggesting future growth and innovation.
- Drug Efficacy and Innovation: (30%) Discussions focus on the potency and effectiveness of drugs like REDEMPLO, emphasizing scientific breakthroughs.
Most Critical Themes:
- Regulatory and Diagnostic Nuances: (30%) Clarifications on FDA approval for REDEMPLO highlight specific diagnostic criteria, which could impact broader adoption.
Top $arwrs Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"If $ARWR's upcoming INHBE data in January confirms what we just saw reported by $WVE I wonder how quickly big pharma might move in. We all know that $PFE and $NVO are a bit desperate"
X Link @EliKorey 2025-12-08T13:22Z XXX followers, XXX engagements
"H.C. Wainwright $ARWR's PT to $XX from $XX and reiterated at a Buy rating. $IONS $REGN ALNY NVS H.C. Wainwright said we view the newly approved REDEMPLO (plozasiran) label as best-in-class across safety convenience and intent-to-treat population breadth. We believe that the label supports an initial launch focused on the FCS rare indication while laying the strategic foundation for expansion into high-risk severe hypertriglyceridemia (sHTG) in 2027. Meanwhile top-line readouts from the sHTG Phase X trials SHASTA-3 SHASTA-4 and MUIR-3 remain on track for 3Q26 which management remains confident"
X Link @Quantumup1 2025-12-03T13:08Z 3919 followers, 1877 engagements